

DAFTAR PUSTAKA

- AAO. (2019). American Academy of Ophthalmology: Glaucoma. Retrieved from <https://www.aao.org/eye-health/diseases/glaucoma-symptoms>
- Adegate, J., Rahmatnejad, K., Waisbourd, M., & Katz, L. J. (2019). Intraocular pressure-independent management of normal tension glaucoma. *Survey of Ophthalmology*, *64*(1), 101–110. doi:10.1016/j.survophthal.2018.08.005
- Agarwal, R., Gupta, S. K., Agarwal, P., Saxena, R., & Agrawal, S. (2009). Current concepts in the pathophysiology of glaucoma. *Indian Journal of Ophthalmology*, *57*(4), 257–266. doi: 10.4103/0301-4738.53049
- Agrawal, A., Singh, A., & Mittal, S. K. (2018). Glaucoma in Asia- An epidemiological perspective. *Nepalese Journal of Ophthalmology*, *9*(2), 208–211. doi:10.3126/nepjoph.v9i2.19273
- Aguayo Bonniard, A., Yeung, J. Y., Chan, C. C., & Birt, C. M. (2016). Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). *Expert Opinion on Drug Metabolism and Toxicology*, *12*(11), 1279–1289. doi:10.1080/17425255.2016.1209481
- Alkozi, H. A., Navarro, G., Aguinaga, D., Reyes-Resina, I., Sanchez-Naves, J., Pérez de Lara, M. J., Pintor, J. (2020). Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure - their disruption contributes to hypertensive glaucoma. *British Journal of Pharmacology*, *177*(9), 2090–2105. doi:10.1111/bph.14971
- Anwar, Z., Wellik, S. R., & Galora, A. (2013). Glaucoma therapy and ocular surface disease: Current literature and recommendations. *Current Opinion in Ophthalmology*, *24*(2), 136–143. doi:10.1097/ICU.0b013e32835c8aba
- Aromataris, E., & Pearson, A. (2014). The systematic review: An overview. *American Journal of Nursing*, *114*(3), 53–58. doi:10.1097/01.NAJ.0000444496.24228.2c
- Assimopoulou, A. N., Sinakos, Z., & Papageorgiou, V. P. (2005). Radical scavenging activity of *Crocus sativus* L. Extract and its Bioactive Constituents. *Phytotherapy Research*, *19*(11), 997–1000. doi:10.1002/ptr.1749
- Azam, M. A., Katz, J., Fashler, S. R., Changoor, T., Azargive, S., & Ritvo, P. (2015). Heart rate variability is enhanced in controls but not maladaptive perfectionists during brief mindfulness meditation following stress-induction: A stratified-randomized trial. *International Journal of Psychophysiology*, *98*(1), 27–34. doi: 10.1016/j.ijpsycho.2015.06.005

- Balasopoulou, A., Kokkinos, P., Pagoulatos, D., Plotas, P., Makri, O. E., Georgakopoulos, C. D., Loukovaara, S. (2017). Lasers in glaucoma. *BMC Ophthalmology*, *17*(1), 1. doi: 10.4103/ijo.IJO
- Benson, H., Beary, J. F., & Carol, M. P. (1974). The Relaxation Response. *Psychiatry*, *37*(1), 37–46. doi: 10.1080/00332747.1974.11023785
- Bertelmann, T., & Stempel, I. (2016). Entspannungsmethoden beim Glaukom: Stellenwert von autogenem Training, Hypnose und Musikmedizin. *Ophthalmologe*, *113*(2), 102–110. doi: 10.1007/s00347-015-0139-y
- Bertelmann, Thomas, & Stempel, I. (2015). “short-term effects of relaxation music on patients suffering from primary open-angle glaucoma.” *Clinical Ophthalmology*, *9*, 2321–2323. doi: 10.2147/OPHTH.S100535
- Bonyadi, M. H. J., Yazdani, S., & Saadat, S. (2014). The ocular hypotensive effect of saffron extract in primary open angle glaucoma: A pilot study. *BMC Complementary and Alternative Medicine*, *14*(1), 1–6. doi: 10.1186/1472-6882-14-399
- Bower, J. E., Crosswell, A. D., Stanton, A. L., Crespi, C. M., Winston, D., Arevalo, J., Ganz, P. A. (2015). Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial. *Cancer*, *121*(8), 1231–1240. doi:10.1002/cncr.29194
- Bower, T. N., Muhsen, S., Overbury, O., Birt, C., & Kasner, O. (2014). Canadian ophthalmologists’ opinions concerning complementary and alternative medicine (CAM) use in Glaucoma. *Journal of Glaucoma*, *23*(7), 430–434. doi:10.1097/IJG.0b013e31827b139d
- Bradt, J., Dileo, C., & Potvin, N. (2013). Music for stress and anxiety reduction in coronary heart disease patients. *Cochrane Database of Systematic Reviews*, *2013*(12). doi:10.1002/14651858.CD006577.pub3
- Buccheri, R. K., & Sharifi, C. (2017). Critical Appraisal Tools and Reporting Guidelines for Evidence-Based Practice. *Worldviews on Evidence-Based Nursing*, *14*(6), 463–472. doi:10.1111/wvn.12258
- Bulechek, G. M., Butcher, H. K., Dochterman, J. M., & Wagner, C. M. (2013). *Nursing Intervention Classification (NIC)* (6th ed.)
- CASP. (2018). CASP Randomised Controlled Trial Checklist. *CASP Checklists Oxford*, (2018), 1–7.
- Casson, R. J., Chidlow, G., Wood, J. P. M., Crowston, J. G., & Goldberg, I. (2012). Definition of glaucoma: Clinical and experimental concepts. *Clinical and Experimental Ophthalmology*, *40*(4), 341–349. doi:10.1111/j.1442-9071.2012.02773.x
- Centre for Evidence-Based Medicine (CEBM). (2011). Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence.

- Chan, M. F., Wong, Z. Y., & Thayala, N. V. (2011). The effectiveness of music listening in reducing depressive symptoms in adults: A systematic review. *Complementary Therapies in Medicine*, 19(6), 332–348. doi:10.1016/j.ctim.2011.08.003
- Chang, H. Y., & Chang, H. L. (2015). A review of nurses' knowledge, attitudes, and ability to communicate the risks and benefits of complementary and alternative medicine. *Journal of Clinical Nursing*, 24(11–12), 1466–1478. doi: 10.1111/jocn.12790
- Chen, S. J., Lu, P., Zhang, W. F., & Lu, J. H. (2012). High myopia as a risk factor in primary open angle glaucoma. *International Journal of Ophthalmology*, 5(6), 750–753. doi: 10.3980/j.issn.2222-3959.2012.06.18
- Chen, Yieh, F. S., Liao, W. L., Li, T. C., & Hsieh, C. L. (2020). Effect of Acupuncture on Intraocular Pressure in Glaucoma Patients: A Single-Blinded, Randomized, Controlled Trial. *Evidence-Based Complementary and Alternative Medicine*, 2020. doi: 10.1155/2020/7208081
- Cherry, B., & Jacob, S. R. (2013). *Contemporary nursing Issues, Trends & management*. *Journal of Chemical Information and Modeling* 53(6). doi:10.1017/CBO9781107415324.004
- Cho, H. kyung, & Kee, C. (2014). Population-based glaucoma prevalence studies in Asians. *Survey of Ophthalmology*, 59(4), 434–447. doi:10.1016/j.survophthal.2013.09.003
- Chu, T. C., & Potter, D. E. (2002). Ocular hypotension induced by electroacupuncture. *Journal of Ocular Pharmacology and Therapeutics*, 18(4), 293–305. doi: 10.1089/10807680260218461
- Chu, T. C., Socci, R. R., Ogidigben, M. J., & Potter, D. E. (1997). Potential mechanisms of moxonidine-induced ocular hypotension: Role of norepinephrine. *Journal of Ocular Pharmacology and Therapeutics*, 13(6), 489–496. doi:10.1089/jop.1997.13.489
- Conlon, R., Saheb, H., & Ahmed, I. I. K. (2017). Glaucoma treatment trends: a review. *Canadian Journal of Ophthalmology*, 52(1), 114–124. doi:10.1016/j.jcjo.2016.07.013
- Cook, J. A., Botello, A. P., Elders, A., Fathi Ali, A., Azuara-Blanco, A., Fraser, C., Margaret Burr, J. (2012). Systematic review of the agreement of tonometers with Goldmann applanation tonometry. *Ophthalmology*, 119(8), 1552–1557. doi: 10.1016/j.ophtha.2012.02.030
- Dada, T., Bhai, N., Midha, N., Shakrawal, J., Kumar, M., Chaurasia, P., Sihota, R. (2020). *Effect Of Mindfulness Meditation On Intraocular Pressure and Trabecular Meshwork Gene Expression: A Randomised Controlled Trial*. *American Journal of Ophthalmology*. doi:10.1016/j.ajo.2020.10.012

- Dada, T., Mittal, D., Mohanty, K., Faiq, M. A., Bhat, M. A., Yadav, R. K., Dada, R. (2018). Mindfulness meditation reduces intraocular pressure, lowers stress biomarkers and modulates gene expression in Glaucoma: A randomized controlled trial. *Journal of Glaucoma*, 27(12), 1061–1067. doi:10.1097/IJG.0000000000001088
- Del Valle Bessone, C., Fajreldines, H. D., de Barboza, G. E. D., Tolosa de Talamoni, N. G., Allemandi, D. A., Carpentieri, A. R., & Quinteros, D. A. (2019). Protective role of melatonin on retinal ganglionar cell: In vitro an in vivo evidences. *Life Sciences*, 218, 233–240. doi:10.1016/j.lfs.2018.12.053
- Denby, K., & Duffy, N. (2011). *Complementary and alternative therapies*. (M. Snider & R. Lindquist, Eds.), *Current and Emerging Treatments for Psoriasis* (6). doi:10.2217/EBO.11.162
- Dikopf, M. S., Vajaranant, T. S., & Edward, D. P. (2017). Topical treatment of glaucoma: established and emerging pharmacology. *Expert Opinion on Pharmacotherapy*, 18(9), 885–898. doi:10.1080/14656566.2017.1328498
- Ebneshahidi, A., & Mohseni, M. (2008). The effect of patient-selected music on early postoperative pain, anxiety, and hemodynamic profile in cesarean section surgery. *Journal of Alternative and Complementary Medicine*, 14(7), 827–831. doi:10.1089/acm.2007.0752
- Eckert, A., Keil, U., Kressmann, S., Schindowski, K., Leutner, S., Leutz, S., & Müller, W. E. (2003). Effects of EGb 761® Ginkgo biloba extract on mitochondrial function and oxidative stress. *Pharmacopsychiatry*, 36. doi:10.1055/s-2003-40449
- Edmunds, B., Thompson, J., Salmon, J., & Wormald, R. (2002). The National Survey of Trabeculectomy . III . Early and late complications, 297–303. doi:10.1038/sj/eye/6700148
- Erb, C., Brody, S., & Rau, H. (1998). Einfluß von mentalem und physischem Streß auf den intraokulären Druck - eine Pilotstudie. *Klinische Monatsblätter Für Augenheilkunde*, 212(05), 270–274. doi: 10.1055/s-2008-1034878
- Eschstruth, & Stempel. (2004). Einfluss akustischer und imaginativer Entspannungsmethoden auf den intraokularen Druck, Musiktherapie beim primären Offenwinkelglaukom. *Philipps-Universität Marburg*. doi:10.17192/z2004.0478
- Foster, P. J., Buhrmann, R., Quigley, H. A., & Johnson, G. J. (2002). Prevalence Surveys, 86(2), 238–243. doi: 10.1136/bjo.86.2.238
- Friedman. (2011). Prevalence of open-angle glaucoma among adults in the United States (Archives of Ophthalmology (2004) 122, 4 (532-538)). *Archives of Ophthalmology*, 129(9), 1224. doi: 10.1001/archophthalmol.2011.261

- Gagrani, M., Faiq, M. A., Sidhu, T., Dada, R., Yadav, R. K., Sihota, R., Dada, T. (2018). Meditation enhances brain oxygenation, upregulates BDNF and improves quality of life in patients with primary open angle glaucoma: A randomized controlled trial. *Restorative Neurology and Neuroscience*, *36*(6), 741–753. doi: 10.3233/RNN-180857
- Garg, S. P., Dada, T., Talwar, D., & Biswas, N. R. (1997). Endogenous cortisol profile in patients with central serous chorioretinopathy. *British Journal of Ophthalmology*, *81*(11), 962–964. doi: 10.1136/bjo.81.11.962
- Goldberg, I. (2003). Relationship between intraocular pressure and preservation of visual field in glaucoma. *Survey of Ophthalmology*, *48*(2 SUPPL. 1), 6–7. doi: 10.1016/S0039-6257(03)00006-7
- Green, C. M., Kearns, L. S., Wu, J., Barbour, J. M., Wilkinson, R. M., Ring, M. A., Mackey, D. A. (2007). How significant is a family history of glaucoma? Experience from the glaucoma inheritance study in Tasmania. *Clinical and Experimental Ophthalmology*, *35*(9), 793–799. doi: 10.1111/j.1442-9071.2007.01612.x
- Guo, X., Kong, X., Huang, R., Jin, L., Ding, X., He, M., Congdon, N. G. (2013). Effect of ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: A randomized, crossover clinical trial. *Investigative Ophthalmology and Visual Science*, *55*(1), 110–116. doi:10.1167/iovs.13-13168
- Gupta, V., Sony, P., Agarwal, H. C., Sihota, R., & Sharma, A. (2006). Inter-instrument agreement and influence of central corneal thickness on measurements with Goldmann, pneumotonometer and noncontact tonometer in glaucomatous eyes. *Indian Journal of Ophthalmology*
- VineyHan, J. S. (2004). Acupuncture and endorphins. *Neuroscience Letters*, *361*(1–3), 258–261. doi: 10.1016/j.neulet.2003.12.019
- Han Ji-Sheng. (2003). Acupuncture:neuropeptide release produced by electrical stimulation of different frequencis. *TRENDS in Neurosciences*, *26*(1), 17–21.
- Her, J. S., Liu, P. L., Cheng, N. C., Hung, H. C., Huang, P. H., Chen, Y. L., Chen, Y. H. (2010). Intraocular pressure-lowering effect of auricular acupressure in patients with glaucoma: A prospective, single-blinded, randomized controlled trial. *Journal of Alternative and Complementary Medicine*, *16*(11), 1177–1184. doi: 10.1089/acm.2010.0020
- Higgins, J. P. T., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., & Oxman, A. D. (2011). The Cochrane Collaboration 's tool for assessing risk of bias in randomised trials, 1–9. doi: 10.1136/bmj.d5928
- Ibrahim Ali, & Fahmy. (2015). Acupuncture as Additional Therapy for Modulation of Intraocular Pressure in Patient with Open Angle Glaucoma Authors. *Journal of Medical Science And Clinical Research*, *03*(07), 6781–6789.

- Iwata, M., Ota, K. T., Li, X. Y., Sakaue, F., Li, N., Dutheil, S., Duman, R. S. (2016). Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. *Biological Psychiatry*, *80*(1), 12–22. doi:10.1016/j.biopsych.2015.11.026
- Izzotti, A., Saccà, S. C., Longobardi, M., & Cartigl, C. (2009). Sensitivity of ocular anterior chamber tissues to oxidative damage and its relevance to the pathogenesis of Glaucoma. *Investigative Ophthalmology and Visual Science*, *50*(11), 5251–5258. doi: 10.1167/iovs.09-3871
- JBI. (2017). The Joanna Briggs Institute Critical Appraisal Checklist for Quasi-Experimental (Non-Randomized Experimental Studies). *The Joanna Briggs Institute*, 7. Retrieved from http://www.JBI_Quasi-Experimental_Appraisal_Tool2017.pdf
- Jia, L.-Y., Sun, L., Dorothy, Lam, D., & Pang, C. P. (2008). Effect of Topical Ginkgo biloba Extract on Steroid-Induced Changes in the Trabecular Meshwork and Intraocular Pressure, *12*(126), 1700–1706. doi:10.1001 / archophthalmol. 2008.512
- Jia, Sun, Fan, Lam, Pang, C. P., & Yam, G. H. F. (2008). Effect of Topical, *126*(12), 1700–1706.
- Joanna Briggs Institute. (2020). *JBI Manual for Evidence Synthesis*. (E. Aromataris & Z. Munn, Eds.), *JBI Manual for Evidence Synthesis*. doi10.46658/JBIMES-20-01
- Kabisch, M., Ruckes, C., Seibert-Grafe, M., & Blettner, M. (2011). Randomized Controlled Trials. *Deutsches Arzteblatt*, *108*(39), 663–668. doi.org/10.3238/arztebl.2011.0663
- Kass, M. A. (2002). The ocular hypertension treatment study. *Journal of Glaucoma*, *3*(2), 97–100. doi: 10.1097/00061198-199400320-00001
- Kementerian Kesehatan RI. (2003). Keputusan Menteri Kesehatan Republik Indonesia Nomor 1076/Menkes/Sk/Vii/2003 Tentang Penyelenggaraan Pengobatan Tradisional, (1), 6–8. doi: 10.16309/j.cnki.issn.1007-1776.2003.03.004
- Kementerian Kesehatan RI. (2019). infoDatin_glaukoma_2019.pdf.
- Kersey, J. P., & Broadway, D. C. (2006). Corticosteroid-induced glaucoma: A review of the literature. *Eye*, *20*(4), 407–416. doi: 10.1038/sj.eye.6701895
- Khanna, S., & Greeson, J. M. (2013). A narrative review of yoga and mindfulness as complementary therapies for addiction. *Complementary Therapies in Medicine*, *21*(3), 244–252. doi: 10.1016/j.ctim.2013.01.008

- Kim, T. H., Kang, J. W., Kim, K. H., Kang, K. W., Shin, M. S., Jung, S. Y., Choi, S. M. (2012). Acupuncture for the treatment of dry eye: A multicenter randomised controlled trial with active comparison intervention (artificial teardrops). *7*(5), 1–9. doi: 10.1371/journal.pone.0036638
- Koelsch, S. (2014). Brain correlates of music-evoked emotions. *Nature Reviews Neuroscience*, *15*(3), 170–180. doi: 10.1038/nrn3666
- Kong, X., Chen, Y., Chen, X., & Sun, X. (2011). Influence of family history as a risk factor on primary angle closure and primary open angle glaucoma in a Chinese population. *Ophthalmic Epidemiology*, *18*(5), 226–232. doi:10.3109/09286586.2011.595040
- Kurusu, M., Watanabe, K., Nakazawa, T., Seki, T., Arai, H., Sasaki, H., Tamai, M. (2005). Acupuncture For Patients With Glaucoma. *Explore: The Journal of Science and Healing*, *1*(5), 372–376. doi:10.1016/j.explore.2005.06.007
- Law, S., Lowe, S., Law, S. M., Giacconi, J. A., Coleman, A. L., & Caprioli, J. (2015). Prospective Evaluation of Acupuncture as Treatment for Glaucoma. *American Journal of Ophthalmology*, *160*(2), 256–265. doi:10.1016/j.ajo.2015.04.033
- Leske, M. C., Heijl, A., Hussein, M., Bengtsson, B., Hyman, L., Komaroff, E., & Lee, P. (2003). Factors for glaucoma progression and the effect of treatment. *Evidence-Based Eye Care*, *4*(4), 196–197. doi: 10.1097/00132578-200310000-00007
- Leszczynska, A., Ramm, L., Spoerl, E., Pillunat, L., & Terai, N. (2018). “the short-term effect of acupuncture on different ocular blood flow parameters in patients with primary open-angle glaucoma: A randomized, clinical study.” *Clinical Ophthalmology*, *12*, 1959–1960. doi: 10.2147/OPTH.S181991
- Lewis, S. L. M., Dirksen, S. R., Heitkemper, M. M., & Bucher, L. (2014). *Medical-Surgical Nursing: Assessment and Management of Clinical Problems*, 1824.
- Lindquist, R., Synder, M., & Tracy, M. F. (2014). *Complementary & alternative therapies in nursing*.
- Lindquist, R., Tracy, M. F., & Snyder, M. (2018). *Complementary and Alternative Therapies in Nursing*. (M. Zuccarini, Ed.) (8th ed.). doi: 10.16309/j.cnki.issn.1007-1776.2003.03.004
- Lusthaus, J., & Goldberg, I. (2019). Current management of glaucoma. *Medical Journal of Australia*, *210*(4), 180–187. doi: 10.5694/mja2.50020
- Maccarone, R., Di Marco, S., & Bisti, S. (2008). Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. *Investigative Ophthalmology and Visual Science*, *49*(3), 1254–1261. doi: 10.1167/iovs.07-0438

- Makri, O. E., Ferlemi, A. V., Lamari, F. N., & Georgakopoulos, C. D. (2013). Saffron administration prevents selenite-induced cataractogenesis. *Molecular Vision*, 19(May), 1188–1197.
- Mantravadi, A. V., & Vadhar, N. (2015). Glaucoma. *Primary Care - Clinics in Office Practice*, 42(3), 437–449. doi: 10.1016/j.pop.2015.05.008
- Marc, Stan, A. and, & Cristina. (2013). Effect of physical and psychological stress on the course of primary open angle glaucoma. *Oftalmologia (Bucharest, Romania): 1990*, 57(2), 60—66. Retrieved from <http://europepmc.org/abstract/MED/24386794>
- Matsuura, M., Hirasawa, K., Murata, H., Nakakura, S., Kiuchi, Y., & Asaoka, R. (2017). Using CorvisST tonometry to assess glaucoma progression. *PLoS ONE*, 12(5), 1–11. doi: 10.1371/journal.pone.0176380
- Mccabe, P., & Jacka, J. (2001). *Complementary Therapies in Nursing And Midwifery: from vision to reality*, 177–196.
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., Altman, D., Antes, G., Tugwell, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Medicine*, 6(7). doi:10.1371/journal.pmed.1000097
- Moorhead, S., Jhonson, M., Maas, M. L., & Swanson, E. (2013). *Nursing Outcomes classification (NOC)* (5)
- Morgan, J. E. (2000). Optic nerve head structure in glaucoma: Astrocytes as mediators of axonal damage. *Eye (Basingstoke)*, 14(3), 437–444. doi:10.1038/eye.2000.128
- NANDA. (2018). *Nursing Diagnosis: Defenitions and Classification, 2018-2020*. (H. Herdman & S. Kamitsuru, Eds.) (11th ed.).
- Nathanson, J. A., & McKee, M. (1995). Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. *Investigative Ophthalmology and Visual Science*, 36(9), 1765–1773.
- Naveen, B., Vk, S., Pai, M., & Shilpa, N. (2014). Assessing Quality of Life in Patients with Glaucoma Using the Glaucoma Quality of Life -15 (GQL-15) Questionnaire in Indian eyes, 4(March), 89–96.
- NCCAM. (2011). Complementary and alternative medicine: What people aged 50 and older discuss with their healthcare providers. *National Institute of Health*, 1–14. Retrieved from https://www.nccih.nih.gov/NCCAM_aarp_survey.pdf

- Newberg, A. B., Wintering, N., Khalsa, D. S., Roggenkamp, H., & Waldman, M. R. (2010). Meditation effects on cognitive function and cerebral blood flow in subjects with memory loss: A preliminary study. *Journal of Alzheimer's Disease*, *20*(2), 517–526. doi: 10.3233/JAD-2010-1391
- Pescosolido, N., Gatto, V., Stefanucci, A., & Rusciano, D. (2015). Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients. *Ophthalmic and Physiological Optics*, *35*(2), 201–205. doi: 10.1111/opo.12189
- Ponte Márquez, P. H., Feliu-Soler, A., Solé-Villa, M. J., Matas-Pericas, L., Filella-Agullo, D., Ruiz-Herrerias, M., Arroyo-Díaz, J. A. (2019). Benefits of mindfulness meditation in reducing blood pressure and stress in patients with arterial hypertension. *Journal of Human Hypertension*, *33*(3), 237–247. doi: 10.1038/s41371-018-0130-6
- Portmann, N., Gugleta, K., Kochkorov, A., Polunina, A., Flammer, J., & Orgul, S. (2011). Choroidal blood flow response to isometric exercise in glaucoma patients and patients with ocular hypertension. *Investigative Ophthalmology and Visual Science*, *52*(10), 7068–7073. doi: 10.1167/iovs.11-7758
- Priya, G., & Kalra, S. (2018). Mind-Body Interactions and Mindfulness Meditation in Diabetes. *Citation: European Endocrinology*, *14*(1), 35–41. doi: 10.17925 / EE.2018.14.1.35
- Quigley, H. A., West, S. K., Rodriguez, J., Munoz, B., Klein, R., & Snyder, R. (2001). The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. *Archives of Ophthalmology*, *119*(12), 1819–1826. doi: 10.1001/archoph.119.12.1819
- Racette, L., Wilson, M. R., Zangwill, L. M., Weinreb, R. N., & Sample, P. A. (2003). Primary open-angle glaucoma in blacks: A Review. *Survey of Ophthalmology*, *48*(3), 295–313. doi: 10.1016/S0039-6257(03)00028-6
- Ramdas, W. D. (2018). The relation between dietary intake and glaucoma: a systematic review. *Acta Ophthalmologica*, *96*(6), 550–556. doi:10.1111/aos.13662
- Razeghinejad, M. R., Myers, J. S., & Katz, L. J. (2011). Iatrogenic glaucoma secondary to medications. *American Journal of Medicine*, *124*(1), 20–25. doi: 10.1016/j.amjmed.2010.08.011
- Rhee, D. J., Katz, L. J., Spaeth, G. L., & Myers, J. S. (2001). Complementary and alternative medicine for glaucoma. *Survey of Ophthalmology*, *46*(1), 43–55. doi: 10.1016/S0039-6257(01)00233-8
- Robertson-Malt, S. (2014). JBIs systematic reviews: Presenting and interpreting findings. *American Journal of Nursing*, *114*(8), 49–54. doi:10.1097/01.NAJ.0000453044.01124.59

- Sabel, B. A., Wang, J., Cárdenas-Morales, L., Faiq, M., & Heim, C. (2018). Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine. *EPMA Journal*, 9(2), 133–160. doi: 10.1007/s13167-018-0136-8
- Schwartz, G. F., & Quigley, H. A. (2008). Adherence and Persistence with Glaucoma Therapy. *Survey of Ophthalmology*, 53(6 SUPPL.), 57–68. doi:10.1016/j.survophthal.2008.08.002
- Shahmansouri, N., Farokhnia, M., Abbasi, S. H., Kassaian, S. E., Noorbala Tafti, A. A., Gougol, A., Akhondzadeh, S. (2014). A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. *Journal of Affective Disorders*, 155(1), 216–222. doi: 10.1016/j.jad.2013.11.003
- Shily, B. G. (1987). Psychophysiological stress, elevated intraocular pressure, and acute closed-angle glaucoma. *Optometry and Vision Science*. doi:10.1097/00006324-198711000-00011
- Shue, B., Chatterjee, A., Fudemberg, S., Jay Katz, L., Moster, M. R., Navarro, M. J., Myers, J. S. (2011). The Effects of Mozart’s music on the performance of glaucoma patients on automated perimetry. *Investigative Ophthalmology and Visual Science*, 52(10), 7347–7349. doi: 10.1167/iovs.11-7430
- Siddaway, A. P., Wood, A. M., & Hedges, L. V. (2018). How to Do a Systematic Review: A Best Practice Guide for Conducting and Reporting Narrative Reviews, Meta-Analyses, and Meta-Syntheses. *Annual Review of Psychology*, 70(1), 747–770. doi: 10.1146 / annurev-psych-010418-102803
- Song, B. J., Aiello, L. P., & Pasquale, L. R. (2016). Presence and Risk Factors for Glaucoma in Patients with Diabetes. *Current Diabetes Reports*, 16(12). doi: 10.1007/s11892-016-0815-6
- Stone, J. (1999). Using complementary therapies within nursing: some ethical and legal considerations. *Complementary Therapies in Nursing & Midwifery*, 5(2), 46–50. doi: 10.1016/S1353-6117(99)80054-7
- Sun, X., & Dai, Y. (2019). *Medical treatment of glaucoma*. (X. Sun & Y. Dai, Eds.), *British Journal of Ophthalmology* (Vol. 40). doi:10.1136/bjo.40.12.765
- Tamm, E. R. (2010). Functional morphology of the trabecular meshwork. *Encyclopedia of the Eye*, 18(1), 157–163. doi: 10.1016/B978-0-12-374203-2.00092-0
- Tang, Y. Y., Lu, Q., Feng, H., Tang, R., & Posner, M. I. (2015). Short-term meditation increases blood flow in anterior cingulate cortex and insula. *Frontiers in Psychology*, 6(FEB), 1–4. doi: 10.3389/fpsyg.2015.00212

- Tham, Y. C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C. Y. (2014). Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. *Ophthalmology*, *121*(11), 2081–2090. doi: 10.1016/j.ophtha.2014.05.013
- Thau, A., Lloyd, M., Freedman, S., Beck, A., Grajewski, A., & Levin, A. V. (2018). New classification system for pediatric glaucoma: Implications for clinical care and a research registry. *Current Opinion in Ophthalmology*, *29*(5), 385–394. doi:10.1097/ICU.0000000000000516
- Tooley, G. A., Armstrong, S. M., Norman, T. R., & Sali, A. (2000). Acute increases in night-time plasma melatonin levels following a period of meditation. *Biological Psychology*, *53*(1), 69–78. doi:10.1016/S0301-0511(00)00035-1
- Turakitwanakan, W., Mekseepralard, C., & Busarakumtragul, P. (2013). Effects of mindfulness meditation on serum cortisol of medical students. *Journal of the Medical Association of Thailand*, *96*
- Wan, M. J., Daniel, S., Kassam, F., Mutti, G., Butty, Z., Kasner, O. Buys, Y. M. (2012). Survey of complementary and alternative medicine use in glaucoma patients. *Journal of Glaucoma*, *21*(2), 79–82. doi:10.1097/IJG.0b013e3182027c0c
- Wang, G. J., Ayati, M. H., & Zhang, W. B. (2010). Meridian Studies in China: A Systematic Review. *JAMS Journal of Acupuncture and Meridian Studies*, *3*(1), 1–9. doi:10.1016/S2005-2901(10)60001-5
- Weinreb, R., Fiscella, R., Greenfield, D., Heuer, D., Singh, K., & Taylor, S. R. (2009). and Patients' Compliance With Glaucoma Therapy Featuring: This continuing medical educational activity is jointly sponsored by the Dulaney Foundation and Glaucoma Today. *Pharmacoeconomics and Patients' Compliance With*, (March).
- Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014). The pathophysiology and treatment of glaucoma: A review. *JAMA - Journal of the American Medical Association*, *311*(18), 1901–1911. doi.org/10.1001/jama.2014.3192
- Weinreb, R. N., Ong, T., Sforzolini, B. S., Vittitow, J. L., Singh, K., Kaufman, P. L. Růžičková, E. (2015). A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma. *British Journal of Ophthalmology*, *99*(6), 738–745. doi:10.1136/bjophthalmol-2014-305908
- Welte, A. K., Hahn, U., Büssing, A., & Krummenauer, F. (2017). Ergebnisse eines systematischen Reviews zu Einsatz und berichtetem therapeutischem Nutzen komplementärmedizinischer Methoden in der Augenheilkunde. *Klinische Monatsblätter Fur Augenheilkunde*, *234*(5), 686–696. doi:10.1055/s-0042-106901

- WHO. (2019). World Health Organization: Blindness and Vision Impairment. Retrieved from <https://www.who.int/blindness-and-visual-impairment>
- Wittes, J. (2002). Sample Size Calculations for Randomized Controlled Trials, 24(1). doi: 10.1093 / epirev / 24.1.39
- Wolfs, R. C. W. (1998). Genetic Risk of Primary Open-angle Glaucoma. *Archives of Ophthalmology*, 116(12), 1640. doi:10.1001/archoph.116.12.1640
- Wordinger, R. J., & Clark, A. F. (1999). Effects of glucocorticoids on the trabecular meshwork: Towards a better understanding of glaucoma. *Progress in Retinal and Eye Research*, 18(5), 629–667. doi:10.1016/S1350-9462(98)00035-4
- Wu, A.-M., Wi Zhou, X., Mi, L.-L., Cheng, B., & Cai, X. (2019). Effects of acupuncture, tuina combined with phacoemulsification for cataract with glaucoma, 39(2), 156–159. doi:10.13703/j.0255-2930.2019.02.012
- Xing, J. jing, Zeng, B. Y., Li, J., Zhuang, Y., & Liang, F. rong. (2013). *Acupuncture point specificity. International Review of Neurobiology* (1st ed., Vol. 111). Elsevier Inc. doi:10.1016/B978-0-12-411545-3.00003-1
- Yeh, T. Y., Lin, J. C., & Liu, C. F. (2016). Effect of transcutaneous electrical nerve stimulation through acupoints of Pucan (BL 61) and Shenmai (BL 62) on intraocular pressure in patients with glaucoma: a randomized controlled trial. *Journal of Traditional Chinese Medicine* 36(1), 51–56. doi:10.1016/s0254-6272(16)30008-5
- Zaccaro, A., Piarulli, A., Laurino, M., Garbella, E., Menicucci, D., Neri, B., & Gemignani, A. (2018). How Breath-Control Can Change Your Life: A Systematic Review on Psycho-Physiological Correlates of Slow Breathing. *Frontiers in Human Neuroscience*, 12(September), 1–16. doi:10.3389/fnhum.2018.00353
- Zhou, L., Li, Y., & Yue, B. Y. J. T. (1999). Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: The trabecular meshwork. *Journal of Cellular Physiology*, 180(2), 182–189. doi:10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X

LAMPIRAN

LAMPIRAN 1. TOOLS PENILAIAN KUALITAS ARTIKEL CASP RCT



CASP Checklist: 11 questions to help you make sense of a **Randomised Controlled Trial**

How to use this appraisal tool: Three broad issues need to be considered when appraising a trial:

- ▶ Are the results of the study valid? (Section A)
- ▶ What are the results? (Section B)
- ▶ Will the results help locally? (Section C)

The 11 questions on the following pages are designed to help you think about these issues systematically. The first three questions are screening questions and can be answered quickly. If the answer to both is "yes", it is worth proceeding with the remaining questions. There is some degree of overlap between the questions, you are asked to record a "yes", "no" or "can't tell" to most of the questions. A number of italicised prompts are given after each question. These are designed to remind you why the question is important. Record your reasons for your answers in the spaces provided.

About: These checklists were designed to be used as educational pedagogic tools, as part of a workshop setting, therefore we do not suggest a scoring system. The core CASP checklists (randomised controlled trial & systematic review) were based on JAMA 'Users' guides to the medical literature 1994 (adapted from Guyatt GH, Sackett DL, and Cook DJ), and piloted with health care practitioners.

For each new checklist, a group of experts were assembled to develop and pilot the checklist and the workshop format with which it would be used. Over the years overall adjustments have been made to the format, but a recent survey of checklist users reiterated that the basic format continues to be useful and appropriate.

Referencing: we recommend using the Harvard style citation, i.e.: *Critical Appraisal Skills Programme (2018). CASP (insert name of checklist i.e. Randomised Controlled Trial) Checklist. [online] Available at: URL. Accessed: Date Accessed.*

©CASP this work is licensed under the Creative Commons Attribution – Non-Commercial-Share A like. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/> www.casp-uk.net

Paper for appraisal and reference:.....

Section A: Are the results of the trial valid?

1. Did the trial address a clearly focused issue?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

HINT: An issue can be 'focused' in terms of

- the population studied
- the intervention given
- the comparator given
- the outcomes considered

Comments:

2. Was the assignment of patients to treatments randomised?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

HINT: Consider

- how this was carried out
- was the allocation sequence concealed from researchers and patients

Comments:

3. Were all of the patients who entered the trial properly accounted for at its conclusion?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

HINT: Consider

- was the trial stopped early
- were patients analysed in the groups to which they were randomised

Comments:

Is it worth continuing?

4. Were patients, health workers and study personnel 'blind' to treatment?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

Comments:

5. Were the groups similar at the start of the trial

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

HINT: Consider
• other factors that might affect the outcome, such as; age, sex, social class

Comments:

6. Aside from the experimental intervention, were the groups treated equally?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

Comments:

Section B: What are the results?

7. How large was the treatment effect?

- HINT: Consider
- what outcomes were measured
 - Is the primary outcome clearly specified
 - what results were found for each outcome

Comments:

8. How precise was the estimate of the treatment effect?

- HINT: Consider
- what are the confidence limits

Comments:

Section C: Will the results help locally?

9. Can the results be applied to the local population, or in your context?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

- HINT: Consider whether
- the patients covered by the trial are similar enough to the patients to whom you will apply this
 - how they differ

Comments:

10. Were all clinically important outcomes considered?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

- HINT: Consider whether
- there is other information you would like to have seen
 - if not, does this affect the decision

Comments:

11. Are the benefits worth the harms and costs?

Yes	<input type="checkbox"/>
Can't Tell	<input type="checkbox"/>
No	<input type="checkbox"/>

- HINT: Consider
- even if this is not addressed by the trial, what do **you** think?

Comments:

LAMPIRAN 2. CENTRE FOR EVIDENCE-BASED MEDICINE

Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009)

What are we to do when the irresistible force of the need to offer clinical advice meets with the immovable object of flawed evidence? All we can do is our best: give the advice, but alert the advisees to the flaws in the evidence on which it is based.

The CEBM ‘Levels of Evidence 1’ document sets out one approach to systematising this process for different question types.

(For definitions of terms used see our [glossary](#))

Level	Therapy / Prevention, Aetiology / Harm	Prognosis	Diagnosis	Differential diagnosis / symptom prevalence study	Economic and decision analyses
1a	SR (with homogeneity*) of RCTs	SR (with homogeneity*) of inception cohort studies; CDR” validated in different populations	SR (with homogeneity*) of Level 1 diagnostic studies; CDR” with 1b studies from different clinical centres	SR (with homogeneity*) of prospective cohort studies	SR (with homogeneity*) of Level 1 economic studies
1b	Individual RCT (with narrow Confidence Interval” _i)	Individual inception cohort study with > 80% follow-up; CDR” validated in a single population	Validating** cohort study with good” ” ” reference standards; or CDR” tested within one clinical centre	Prospective cohort study with good follow-up****	Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses
1c	All or none§	All or none case-series	Absolute SpPins and SnNouts” “	All or none case-series	Absolute better-value or worse-value analyses ” ” ” “
2a	SR (with homogeneity*) of cohort studies	SR (with homogeneity*) of either retrospective cohort studies or untreated control groups in RCTs	SR (with homogeneity*) of Level >2 diagnostic studies	SR (with homogeneity*) of 2b and better studies	SR (with homogeneity*) of Level >2 economic studies
2b	Individual cohort study (including low quality RCT; e.g., <80% follow-up)	Retrospective cohort study or follow-up of untreated control patients in an RCT; Derivation of CDR” or	Exploratory** cohort study with good” ” ” reference standards; CDR” after derivation, or validated only on	Retrospective cohort study, or poor follow-up	Analysis based on clinically sensible costs or alternatives; limited review(s) of the evidence, or single studies; and

		validated on split-sample§§§ only	split-sample§§§ or databases		including multi-way sensitivity analyses
2c	“Outcomes” Research; Ecological studies	“Outcomes” Research		Ecological studies	Audit or outcomes research
3a	SR (with homogeneity*) of case-control studies		SR (with homogeneity*) of 3b and better studies	SR (with homogeneity*) of 3b and better studies	SR (with homogeneity*) of 3b and better studies
3b	Individual Case-Control Study		Non-consecutive study; or without consistently applied reference standards	Non-consecutive cohort study, or very limited population	Analysis based on limited alternatives or costs, poor quality estimates of data, but including sensitivity analyses incorporating clinically sensible variations.
4	Case-series (and poor quality cohort and case-control studies§§)	Case-series (and poor quality prognostic cohort studies***)	Case-control study, poor or non-independent reference standard	Case-series or superseded reference standards	Analysis with no sensitivity analysis
5	Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles”	Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles”	Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles”	Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles”	Expert opinion without explicit critical appraisal, or based on economic theory or “first principles”

Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009.

Notes

Users can add a minus-sign “-” to denote the level of that fails to provide a conclusive answer because:

- **EITHER** a single result with a wide Confidence Interval
- **OR** a Systematic Review with troublesome heterogeneity.

Such evidence is inconclusive, and therefore can only generate Grade D recommendations.

*	By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all systematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant. As noted above, studies displaying worrisome heterogeneity should be tagged with a “-” at the end of their designated level.
“	Clinical Decision Rule. (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category.)
“ _i	See note above for advice on how to understand, rate and use trials or other studies with wide confidence intervals.
§	Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became available, but none now die on it.
§§	By poor quality cohort study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a sufficiently long and complete follow-up of patients. By poor quality case-control study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
§§§	Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into “derivation” and “validation” samples.
” “	An “Absolute SpPin” is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An “Absolute SnNout” is a diagnostic finding whose Sensitivity is so high that a Negative result rules-out the diagnosis.
“ _i ” _i	Good, better, bad and worse refer to the comparisons between treatments in terms of their clinical risks and benefits.
” ” “	Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference standards are haphazardly applied, but still independent of the test. Use of a non-independent reference standard (where the ‘test’ is included in the ‘reference’, or where the ‘testing’ affects the ‘reference’) implies a level 4 study.
” ” ” “	Better-value treatments are clearly as good but cheaper, or better at the same or reduced cost. Worse-value treatments are as good and more expensive, or worse and the equally or more expensive.
**	Validating studies test the quality of a specific diagnostic test, based on prior evidence. An exploratory study collects information and trawls the data (e.g. using a regression analysis) to find which factors are ‘significant’.
***	By poor quality prognostic cohort study we mean one in which sampling was biased in favour of patients who already had the target outcome, or the measurement of outcomes was accomplished in <80% of study patients, or outcomes were determined in an unblinded, non-objective way, or there was no correction for confounding factors.
****	Good follow-up in a differential diagnosis study is >80%, with adequate time for alternative diagnoses to emerge (for example 1-6 months acute, 1 – 5 years chronic)

Grades of Recommendation

A	consistent level 1 studies
B	consistent level 2 or 3 studies <i>or</i> extrapolations from level 1 studies
C	level 4 studies <i>or</i> extrapolations from level 2 or 3 studies
D	level 5 evidence <i>or</i> troublingly inconsistent or inconclusive studies of any level

LAMPIRAN 4. PENILAIAN RESIKO BIAS

Tables

Table 1 | Cochrane Collaboration's tool for assessing risk of bias (adapted from Higgins and Altman13)

Bias domain	Source of bias	Support for judgment	Review authors' judgment (assess as low, unclear or high risk of bias)
Selection bias	Random sequence generation	Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups	Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence
	Allocation concealment	Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrolment	Selection bias (biased allocation to interventions) due to inadequate concealment of allocations before assignment
Performance bias	Blinding of participants and personnel*	Describe all measures used, if any, to blind trial participants and researchers from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective	Performance bias due to knowledge of the allocated interventions by participants and personnel during the study
Detection bias	Blinding of outcome assessment*	Describe all measures used, if any, to blind outcome assessment from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective	Detection bias due to knowledge of the allocated interventions by outcome assessment
Attrition bias	Incomplete outcome data*	Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition or exclusions where reported, and any reinclusions in analyses for the review	Attrition bias due to amount, nature, or handling of incomplete outcome data
Reporting bias	Selective reporting	State how selective outcome reporting was examined and what was found	Reporting bias due to selective outcome reporting
Other bias	Anything else, ideally prespecified	State any important concerns about bias not covered in the other domains in the tool	Bias due to problems not covered elsewhere

*Assessments should be made for each main outcome or class of outcomes.

LAMPIRAN 5. PRISMA CHECKLIST

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	i
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	34
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	34-35
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	35
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	36-38
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	39
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	38-39
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	40
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	40
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	41
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	41

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	61-62
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	-
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	43
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	44
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	61-62
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	44-53
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	49
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	61-63
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). / synthesis of evidence (CEBM)	59-63
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	63
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	76
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	77
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	78

